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DEVELOPMENT OF AN OPIOID ROTATION MODEL
Magar RS1, Fine PG2, White RE3,Victor TW3
1PharmIdeas USA, Buffalo, NY, USA, 2University of Utah—Pain
Research Center, Salt Lake City, UT, USA, 3Endo Pharmaceuticals,
Chadds Ford, PA, USA
OBJECTIVE: To develop a model characterizing the phenomena
of opioid rotation for chronic non-cancer pain. METHODS:
Literature review, supplemented by a panel of two pain special-
ists and one oncologist completed a questionnaire to provide
guidance on the typical treatment pathway of care for patients
requiring chronic long acting opioids for chronic non-cancer
pain. Guidance included management of commonly reported side
effects, frequency of follow up, dose adjustment and switch cri-
teria. RESULTS: A model reﬂecting three treatment arms was
constructed based on feedback from the panel: 1) MS Contin ER
switch to OPANA ER; 2) MS Contin ER switch to OxyContin
ER; 3) and OPANA ER switch to OxyContin ER for patients
where morphine is not an appropriate ﬁrst line treatment option.
Clinicians will evaluate the effectiveness and safety within 7–14
days to determine the need for drug switch or dose adjustment. If
a dose adjustment or medication switch is required, further
follow up within 7–14 days will take place. Most patients’ pain
is likely to be controlled with tolerable side effects within the ﬁrst
28–42 days of initiation of therapy. For patients not controlled,
dose adjustment, switching or consultation with a pain specialist
may be required. Over the course of one year, up to 50 different
pathways were possible for each treatment arm which may
include two or more different opioids and up to ﬁve dose
adjustments. CONCLUSION: Opioid rotation is not well char-
acterized. Switching medications, adjusting dose and frequent
follow-up, contribute to incremental costs. Appropriate selection
of second or third line therapy should include consideration for
patient tolerability. Further analysis from a long-term registry
currently underway may provide further guidance for validating
the proposed model in order to better evaluate the cost impact of
switching, frequency of physician contacts, and dose adjustments
associated with opioid rotation.
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DIAGNOSIS ANDTREATMENT FLOWS FOR MORBIDLY OBESE
PATIENTSVISITING PHYSICIAN OFFICES INTHE US
Pokras S, Klingman D,Tierce J
IMS Consulting, Falls Church,VA, USA
OBJECTIVE: To understand the relationship between morbidly
obese patients’ reasons for ofﬁce visits, physicians’ diagnoses of
obesity, and obesity treatments, using a patient ﬂow model.
METHODS: We used the 2005 National Ambulatory Medical
Care Survey, a nationally representative survey of visits to non-
federal ofﬁce-based physicians, including specialists. Patients
with body mass index (BMI) >=40 were categorized as morbidly
obese, based on ofﬁce-recorded height and weight. We created a
patient ﬂow model to study obesity diagnosis rates based on
patients’ stated reasons for visit, and obesity treatment rates
based on type of diagnosis. Reported percentages are based on
weighted frequency counts. RESULTS: In 2005, there were 962.7
million ofﬁce visits by non-pregnant adults (>=18 yrs) of which
38.7% had both height and weight recorded. Of these, 24.1
million (6.5%) visits were made by morbidly obese patients. Less
than 5% stated weight gain as a reason for visit. The rate of
physician diagnosis of obesity was 12.0%, with an additional
38.6% noted (but not diagnosed) as obese, leaving 49.4%
neither diagnosed nor noted as obese. Obesity diagnosis rates
greatly improved when patients stated weight gain as a reason for
visit (81.5%). Overall only 2.1% received an obesity prescrip-
tion, 38.7% received health education for weight reduction, diet/
nutrition or exercise, and 59.2% received none of the above.
Treatment rates improved signiﬁcantly with an obesity diagnosis,
with 4.2% receiving an obesity prescription and 80.1% receiving
health education. CONCLUSION: Among morbidly obese
patients, the rate of physician diagnosis and treatment is very
low. However, rates improve when patients state weight gain as
a concern. These patient ﬂows clearly demonstrate that both the
patient and physician have a shared responsibility in addressing
the condition and efforts are needed to further involve both
stakeholders in tackling the obesity epidemic.
POSTER SESSION II
RESEARCH ON METHODS & CONCEPTUAL
PAPERS—Clinical Outcomes Studies
PMC1
SEARCH STRATEGIES AND RESULTS OF SYSTEMATIC
REVIEWS
Proudfoot C, Plested M, Buckley F
Heron Evidence Development Ltd, Letchworth Garden City,
Hertfordshire, UK
OBJECTIVE: A systematic review is the preferred approach for
assembling clinical evidence. The gold standard for literature
searching comprises sensitive search strategies applied to mul-
tiple literature databases and hand-searching of journals and
conference abstracts. As a follow-up to a previous ISPOR poster,
we sought to evaluate the impact of different search approaches
on the pooled statistical results from systematic reviews, rather
than simply numbers of studies included. METHODS: Previ-
ously, we selected a series of published Cochrane systematic
reviews and compared the effect of more limited search strategies
(a search of multiple literature databases without grey literature,
and a Medline keyword search) on the number of included
studies. We extended this work to compare the pooled effect sizes
resulting from meta-analyses of key outcomes from the studies
included in each search strategy. The reviews covered ﬁve differ-
ent areas: smoking cessation, non-small cell lung cancer, neuro-
pathic pain, acupuncture and Crohn’s disease. All meta-analyses
where studies were missed by lower level searches were re-run
including only the studies retrieved by these searches. This
allowed the impact of missing studies on the meta-analysis result
to be assessed. RESULTS: Differences between meta-analysis
results were generally fairly minimal, although in some cases
missing studies changed the result of a meta-analysis from a
signiﬁcant to a non-signiﬁcant result. In several cases lower level
searches resulted in there being no studies at all looking at
particular outcomes. For example, in a review of neuropathic
pain treatments, which showed a signiﬁcant effect of antidepres-
sants versus placebo on atypical facial pain relief (RR = 1.67),
both studies included in the meta-analysis were absent when
searching with a Medline keyword search only. CONCLU-
SIONS: A comprehensive search strategy is needed to retrieve all
relevant studies in a systematic review. Less comprehensive
searches impact results of meta-analyses and can distort the
evidence base.
PMC2
WHEN ARE INDIRECT AND MIXEDTREATMENT
COMPARISONS BIASED? A GRAPHICAL EXPLANATION
WITH DAGS
Jansen JP
Mapi Values, Boston, MA, USA
In the absence of head-to-head randomized studies, often indirect
treatment comparisons are performed for reimbursement sub-
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missions. Often it is mentioned that in order to obtain unbiased
estimates based on indirect comparisons the distribution of char-
acteristics of the patients included in the different trials needs to
be similar, as well as the study design. By means of directed
acyclic graphs (DAGs), which are often used in epidemiology for
inferences, it is explained that indirect and mixed treatment
comparisons are biased when differences in patient characteris-
tics and trial design do act as an effect modiﬁer of the treatment
effect. Furthermore, the graphs can be used to differentiate
between heterogeneity, selection, and confounding bias. DAGs
for indirect comparisons of RCTs are compared with DAGs for
head-to-head randomized designs and meta-analysis of RCTs.
RESEARCH ON METHODS & CONCEPTUAL
PAPERS—Cost Studies
PMC3
METHODS FOR ESTIMATING CONFIDENCE INTERVALS OF
PER MEMBER PER MONTH (PMPM) UTILIZATION RATES
Saverno K1, Goodman M2
1University of Arizona College of Pharmacy,Tucson, AZ, USA,
2Xcenda,Woodbury, MN, USA
OBJECTIVES: Per member per month (PMPM) utilization rates
are commonly reported in the medical literature to compare
differences in costs and other outcomes across various health care
technologies and interventions. A limitation of PMPM estimates
is that a conﬁdence limit around the point estimate is not obvious
or available from standard statistical software. Our objective is
to demonstrate various methods of calculating conﬁdence inter-
vals for PMPM utilization rates. METHODS: Several methods
were used to estimate conﬁdence intervals surrounding PMPM
estimates including Fieller’s method and Monte-Carlo (MC)
simulation. Women with at least one prescription ﬁll for alendr-
onate, risedronate, or ibandronate during 2006 in a large
managed care data set were used as a sample to generate PMPM
estimates and 95% conﬁdence intervals for bisphosphonate drug
cost, all hospitalization cost, hospital days, and number of hos-
pital admissions during the calendar year of 2006. RESULTS:
There were 34,675 women in our sample. The PMPM estimate
of bisphosphonate drug cost was $23.48. The 95% conﬁdence
intervals generated by the Fieller and MC methods were ($23.21,
$23.75) and ($23.45, $23.87), respectively. The PMPM hospi-
talization cost was $242.28: Fieller and MC 95% conﬁdence
intervals were ($221.53, $263.03) and ($227.74, $259.99),
respectively. The PMPM estimate of hospital days was 0.108
days: Fieller and MC 95% conﬁdence intervals were (0.098,
0.118) and (0.100, 0.116), respectively. The PMPM point esti-
mate for number of hospital admissions was 0.0137: Fieller
and MC 95% conﬁdence intervals were (0.0131, 0.0142) and
(0.0133, 0.0142), respectively. CONCLUSION: The Fieller and
MC simulation methods produced similar conﬁdence intervals
for PMPM estimates for each of the outcomes of interest. Use of
these methods would improve the utility of PMPM point esti-
mates in comparing health care technologies.
PMC4
THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS
ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC
EVALUATIONS
Greenberg D1, Cohen JT2, Neumann PJ2
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Tufts-New
England Medical Center, Boston, MA, USA
Cost-effectiveness acceptability curves (CEACs) plot the prob-
ability that one treatment is more cost-effective than another, as
a function of a societal threshold willingness to pay for addi-
tional units of efﬁcacy (e.g., life-year or QALY gained). OBJEC-
TIVES: To assess the adoption and diffusion rates of CEACs
within the ﬁeld of economic evaluations. METHODS: We used
the Tufts-New England Medical Center registry of 620 published
cost-effectiveness analyses (CEA), presenting an original cost/
QALY ratio from 2002–2005 (http://www.tufts-nemc.org/
cearegistry/). For each CEA we recorded the year of publication,
journal’s name, study origin (country), and a subjective assess-
ment of overall study quality ranging from 1 (low) to 7 (high).
We used univariate analyses (chi-square and t-test), to assess
differences in CEAC use by year of publication, study origin and
quality. We also compared practices in journals publishing a
high-volume (n  10) versus low-volume (n < 10) of CEAs
during the study period. We used multivariable logistic regression
to identify factors predicting CEAC use. RESULTS: Approxi-
mately one ﬁfth (20.2%) of CEAs presented a CEAC. The adop-
tion of CEACs has increased over time from 5.3% (2002) to
30.4% (2005) (p < 0.0001). Studies using CEAC were of higher
quality (4.6  1.0 vs.4.1  0.9; p < 0.0001) and more prevalent
in high-volume journals (30.7% vs. 16.4%; p < 0.0001). CEACs
were more frequently used in UK studies (48.8%) versus studies
from Sweden (24.1%), The Netherlands (17.9%), United States
(11.7%), and Canada (9.1%). Signiﬁcant predictors for using
CEACs were study quality (OR 1.96; 95% CI-1.53–2.51), pub-
lication in a high-volume journal (OR 1.85; 95% CI-1.18–2.89),
and year of publication. CONCLUSIONS: CEACs have been
rapidly adopted, especially among UK-based investigators. If
CEACs turn out to be a useful tool to decision makers, this trend
is encouraging, but means to achieve more rapid deployment
should be identiﬁed.
PMC5
AN ANATOMY OF PHARMACEUTICAL COST-UTILITY
ANALYSES, 1976–2005
Fang C, Cohen JT, Neumann PJ
Tufts-New England Medical Center, Boston, MA, USA
OBJECTIVE: To review and critically evaluate published cost-
utility analysis (CUA) research on pharmaceuticals for the
past three decades. METHODS: We examined data from the
Tufts-NEMC Cost-Effectiveness Analysis Registry www.tufts-
nemc.org/cearegistry), which contains detailed information on
over 1100 CUAs and 3000 cost-utility ratios (in $US2005) pub-
lished from 1976–2005. RESULTS: Of 1164 CUAs published
through 2005, 518 (44.5%) pertain to pharmaceuticals. The
proportion of all CUAs that focus on pharmaceuticals increased
from 32% prior to 1990 to 48% from 1990–2005. U.S.-based
investigators account for 53.6% of the total (47.5% of pharma-
ceutical studies), though the relative proportion of US-based
studies has decreased over time. The U.K.’s share of total pub-
lished CUAs increased from 7% in 1990 to 18% in 2005. The
quality of study (as measured by a subjective 1–7 scale) did not
differ by type of sponsorship (4.4 for industry vs. 4.55 for non-
industry, p = 0.44). The leading journals for publishing pharma-
ceutical CUAs were Pharmacoeconomics (58 CUAs), Ann Intern
Med (47), Int J Technol Assess Health Care (37), JAMA (34) and
Am J Med (25). About 38% of pharmaceutical CUAs were
sponsored by pharmaceutical companies, 27% by non-industry
sources (and in 35% the source of funding could not be deter-
mined). Pﬁzer (26), Norvatis (25), Schering Plough (23), GSK
(21) and Roche (19) have funded the most pharmaceutical CUAs.
The median of 1055 pharmaceutical CE ratios is $26,000/QALY
and is lower for industry vs. non-industry funded studies
(p = 0.004). In multivariate analysis adjusting for factors such as
sponsor type, pharmaceutical CE ratios are similar to others—
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